Items Tagged ‘ALK-Positive Non-Small Cell Lung Cancer’

June 9th, 2017

FDA Expands use of Zykadia® in First-Line ALK-Positive Non-Small Cell Lung Cancer

By

The US Food and Drug Administration (FDA) approved the expanded use of Zykadia® (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose cancers are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test. About Zykadia Zykadia is an oral, selective inhibitor of ALK, a gene that can fuse […]

View full entry

Tags: ALK-Positive Non-Small Cell Lung Cancer, ceritinib, Lung Cancer, News, precision medicine, Zykadia